Expert Analysis

CME

Key Studies in Lymphomas: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 26, 2021

Expiration: February 25, 2022

John M. Burke
John M. Burke, MD
Jeffrey P. Sharman
Jeffrey P. Sharman, MD

Activity

Progress
1
Course Completed

In this activity, John M. Burke, MD, and Jeff P. Sharman, MD, discuss key study findings in lymphomas and chronic lymphocytic leukemia (CLL) presented at the 2020 Virtual ASH Annual Meeting, including results from multiple studies of emerging agents and therapeutic strategies.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with hematologic malignancies do you provide care for in a typical month?

When presenting new data reported at the ASH 2020 meeting to your clinical team, which of the following would you tell them is TRUE of the phase II CAPTIVATE trial, in which patients with CLL/SLL were treated with first-line ibrutinib plus venetoclax followed by continued MRD-guided therapy?

A patient asks if there are any data with CAR T-cell therapies for treating patients with chronic lymphocytic leukemia (CLL). Which of the following would you tell him or her is a CAR T-cell therapy currently being assessed in a clinical trial for treating patients with R/R CLL (as of February 2021), with new data from this trial presented at ASH 2020?

You and a colleague are discussing encouraging findings presented at ASH 2020 from the phase II CITADEL-204 evaluating the novel agent parsaclisib for relapsed/refractory (R/R) marginal zone lymphoma (MZL). Which of the following molecules is inhibited by parsaclisib?